Ghent University Academic Bibliography

Your filters: cql: author="Grönberg, Henrik" or (type any "bookEditor issueEditor" and editor="Grönberg, Henrik")

Add to list
- Journal Article
- A1
- open access
AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Jan Vanwelkenhuyzen (UGent) , Eva Van Bos, Siska Van Bruwaene, Karl Lesage, Alex Maes, Sezgin Üstmert, Filip Lavent, Laurence Beels, Henrik Grönberg, Piet Ost (UGent) , et al.

(2023) EUROPEAN UROLOGY OPEN SCIENCE. 53. p.63-66
Add to list
- Conference Paper
- C3
Inferring the genomic landscape of lymph-node positive high-risk prostate cancer

Jan Vanwelkenhuyzen (UGent) , Kim Van der Eecken (UGent) , Bram De Laere (UGent) , Simon Sundling, Rebecka Bergström, Johan Lindberg, Katleen De Preter (UGent) , Henrik Grönberg and Piet Ost (UGent)

(2020) 7th edition of the annual BMUC meeting, Abstracts.
Add to list
- Journal Article
- A1
- open access
The ProBio trial : molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Alessio Crippa, Bram De Laere (UGent) , Andrea Discacciati, Berit Larsson, Jason T. Connor, Erin E. Gabriel, Camilla Thellenberg, Elin Janes, Gunilla Enblad, Anders Ullen, et al.

(2020) TRIALS. 21(1).
Add to list
- Journal Article
- A1
- open access
Has the PROPHECY of AR-V7 been fulfilled?

Bram De Laere, Piet Ost (UGent) , Henrik Gronberg and Johan Lindberg

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(24). p.2181-2182
Add to list
- Journal Article
- A1
- open access
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, et al.

(2019) CLINICAL CANCER RESEARCH. 25(6). p.1766-1773
Add to list
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Bram De Laere, Prabhakar Rajan, Henrik Gronberg, Luc Dirix, Johan Lindberg, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, et al.

(2019) JAMA ONCOLOGY. 5(7). p.1060-1062
Add to list
- Journal Article
- A1
- open access
Shared heritability and functional enrichment across six solid cancers

Xia Jiang, Hilary K Finucane, Fredrick R Schumacher, Stephanie L Schmit, Jonathan P Tyrer, Younghun Han, Kyriaki Michailidou, Corina Lesseur, Karoline B Kuchenbaecker, Joe Dennis, et al.

(2019) NATURE COMMUNICATIONS. 10.
Add to list
- Journal Article
- A1
- open access
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Markus Mayrhofer, Bram De Laere, Tom Whitington, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, Lucien Hoekx, Dirk Schrijvers, et al.

(2018) GENOME MEDICINE. 10.
Add to list
- Journal Article
- A1
- open access
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

Tokhir Dadaev, Edward J. Saunders, Paul J. Newcombe, Ezequiel Anokian, Daniel A. Leongamornlert, Mark N. Brook, Clara Cieza-Borrella, Martina Mijuskovic, Sarah Wakerell, Ali Amin Al Olama, et al.

(2018) NATURE COMMUNICATIONS. 9.
Add to list
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Fredrick R. Schumacher, Ali Amin Al Olama, Sonja I. Berndt, Sara Benlloch, Mahbubl Ahmed, Edward J. Saunders, Tokhir Dadaev, Daniel Leongamornlert, Ezequiel Anokian, Clara Cieza-Borrella, et al.

(2018) NATURE GENETICS. 50(7). p.928-936

Academic Bibliography

AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Inferring the genomic landscape of lymph-node positive high-risk prostate cancer

The ProBio trial : molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Has the PROPHECY of AR-V7 been fulfilled?

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Shared heritability and functional enrichment across six solid cancers

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Contents

Support

Contact